Home49BA • FRA
add
BeOne Medicines AG
Previous close
€302.00
Day range
€302.00 - €308.00
Year range
€166.00 - €322.00
Market cap
346.87B HKD
Avg Volume
5.00
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 1.41B | 41.00% |
Operating expense | 1.05B | 10.64% |
Net income | 124.84M | 202.88% |
Net profit margin | 8.84 | 172.94% |
Earnings per share | 1.09 | 267.89% |
EBITDA | 198.86M | 496.46% |
Effective tax rate | 15.17% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 4.04B | 48.74% |
Total assets | 7.63B | 31.04% |
Total liabilities | 3.50B | 47.29% |
Total equity | 4.13B | — |
Shares outstanding | 110.66M | — |
Price to book | 8.09 | — |
Return on assets | 5.85% | — |
Return on capital | 8.20% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 124.84M | 202.88% |
Cash from operations | 402.55M | 113.70% |
Cash from investing | -49.27M | 63.20% |
Cash from financing | 961.27M | 7,491.79% |
Net change in cash | 1.32B | 1,286.91% |
Free cash flow | 306.27M | 120.68% |
About
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Founded
Oct 28, 2010
Website
Employees
11,000
